Phase II Trial Shows NestaCell® Dental Pulp Stem Cell Therapy Significantly Improves Motor Function in Huntington's Disease Patients
核心洞察
A randomized, double-blind Phase II trial of NestaCell® (搜索) demonstrated significant improvements in motor function scores compared to placebo in 35 Huntington's disease (搜索) patients over 10 months.
Both tested doses (1 and 2 million cells/kg) showed statistically significant benefits on the primary endpoint UHDRS-TMS, with the higher dose also improving functional capacity measures.
The therapy exhibited a favorable safety profile with only mild treatment-related adverse events including hair changes and phlebitis, supporting advancement to Phase III trials.
A groundbreaking Phase II clinical trial has demonstrated that NestaCell® (搜索), an innovative human dental pulp stem cell therapy, significantly improves motor function in patients with Huntington's disease (搜索) compared to placebo. The randomized, double-blind study represents the first successful cell therapy trial for this devastating neurodegenerative disorder, offering new hope for patients facing a condition with no approved disease-modifying treatments.
Trial Design and Patient Population
The prospective, placebo-controlled trial enrolled 35 patients with genetically confirmed Huntington's disease (搜索) across three treatment arms: 14 patients received NestaCell® (搜索) at 1 million cells/kg, 14 received 2 million cells/kg, and 7 received placebo. Participants underwent nine intravenous infusions over 10 months, administered in three cycles of monthly treatments separated by 60-day intervals.
All enrolled patients had CAG repeat expansions of 40-49, UHDRS Total Motor Scores of at least 5, and Total Functional Capacity scores between 8-11, representing early to moderate disease stages. The study achieved a 91.4% completion rate, with 32 patients finishing all treatment cycles.
Significant Motor Function Improvements
The trial met its primary endpoint with remarkable success. Both NestaCell® (搜索) dose groups showed statistically significant improvements in the Unified Huntington's Disease (搜索) Rating Scale Total Motor Score (UHDRS-TMS) compared to placebo over one year. The pooled treatment groups demonstrated superior outcomes versus placebo (p = 0.005), with individual significance for both the 1 million/kg group (p = 0.009) and 2 million/kg group (p = 0.017).
"Both doses of NestaCell® (搜索) were associated with clinical improvement, whereas the placebo group exhibited disease progression, supporting the therapeutic benefit of NestaCell® for the primary outcome," the researchers reported. This finding is particularly significant given that Huntington's disease (搜索) patients typically decline by approximately 3 points per year on the UHDRS-TMS scale.
Functional Capacity Benefits
Secondary endpoint analyses revealed additional therapeutic benefits. The higher dose group (2 million cells/kg) showed significant improvement in Total Functional Capacity compared to placebo (p = 0.011), with a trend toward benefit observed in the lower dose group (p = 0.068). These findings suggest NestaCell® (搜索) may help preserve patients' ability to perform daily activities and maintain independence.
Brain imaging analyses using diffusion tensor imaging showed trends toward white matter preservation in treated patients compared to placebo, though motion artifacts from chorea limited the interpretability of these results.
Favorable Safety Profile
The therapy demonstrated excellent tolerability throughout the 10-month treatment period. Only six treatment-related adverse events were reported across all patients, primarily involving reversible hair changes such as increased growth or darkening of grey hair. One patient experienced mild phlebitis at the injection site.
A single serious adverse event occurred in the lower dose group - a hospitalization for sinusitis deemed unrelated to treatment. No treatment-related serious adverse events were observed, supporting the therapy's safety profile even with repeated administrations.
Unique Mechanism and Manufacturing
NestaCell® (搜索) consists of cryopreserved human dental pulp stem cells derived from deciduous teeth of healthy pediatric donors aged 5-12 years. These cells express high levels of brain-derived neurotrophic factor (BDNF) and nestin (搜索), a protein supporting axon growth. The cells' low expression of HLA-DR antigens enables administration without immunosuppression.
The manufacturing process follows Good Manufacturing Practices and includes comprehensive quality control testing for sterility, viability, and genetic stability. Phenotypic characterization confirms expression of mesenchymal stem cell markers CD105, CD90, and CD73 while lacking hematopoietic markers.
Comparison to Other Investigational Therapies
The results contrast sharply with other recent Huntington's disease (搜索) trials. The GENERATION HD1 trial of tominersen, an antisense oligonucleotide targeting mutant huntingtin (搜索) mRNA, was terminated early due to lack of efficacy and safety concerns. Pepinemab, a monoclonal antibody targeting neuroinflammation, failed to show significant improvements in UHDRS parameters.
Previous cell therapy attempts using fetal ganglionic eminence cells via intracerebral grafting showed no clinical benefit and high rates of procedural adverse events. NestaCell® (搜索)'s intravenous delivery method offers significant advantages in terms of safety and patient convenience.
Clinical Implications and Future Development
The study's lead investigators noted that "given the progressive nature of HD, where patients typically decline by ~3 points per year on the UHDRS-TMS, even disease stabilization may be considered clinically meaningful." The observed improvements in both motor and functional domains suggest broader clinical efficacy than previously tested therapies.
The researchers concluded that the findings "justify further investigation in a larger, multicentre Phase III trial to validate efficacy, monitor long-term safety, and explore biomarker correlations." The consistent benefits across both dose levels strengthen the case for advancing this therapy to pivotal trials.
Study Limitations and Considerations
The single-center design and relatively small sample size represent typical constraints for rare disease trials. Baseline imbalances showed milder disease in the higher dose group, though both treatment arms demonstrated significant benefits. The COVID-19 pandemic disrupted some recruitment and follow-up schedules, potentially introducing additional variability.
Despite these limitations, the trial's robust primary endpoint results and favorable safety profile establish NestaCell® (搜索) as a promising therapeutic candidate for Huntington's disease (搜索), a condition affecting an estimated 13,000-19,000 gene carriers in Brazil and 2.71 cases per 100,000 individuals globally.